Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MIST
stocks logo

MIST

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.190
-0%
--
--
-0.230
-25.81%
--
--
-0.300
+50%
Estimates Revision
The market is revising No Change the revenue expectations for Milestone Pharmaceuticals Inc. (MIST) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 46.67%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-12.45%
In Past 3 Month
Stock Price
Go Up
up Image
+46.67%
In Past 3 Month
Wall Street analysts forecast MIST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIST is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast MIST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIST is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.640
sliders
Low
4.00
Averages
4.50
High
5.00
Current: 2.640
sliders
Low
4.00
Averages
4.50
High
5.00
Wells Fargo
Overweight
initiated
$4
2025-09-11
Reason
Wells Fargo
Price Target
$4
2025-09-11
initiated
Overweight
Reason
Wells Fargo initiated coverage of Milestone Pharmaceuticals with an Overweight rating and $4 price target. The company is developing Etripamil, a nasal administered, short-acting, calcium channel blocker for the treatment of paroxysmal supraventricular tachycardia, the analyst tells investors in a research note. The firm views Etripamil as "highly differentiated" versus the standard of care and sees the potential for it to emerge as one of the key drugs for acute treatment.
H.C. Wainwright
Brandon Folkes
initiated
$5
2025-06-05
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$5
2025-06-05
initiated
Reason
H.C. Wainwright analyst Brandon Folkes assumed coverage of Milestone Pharmaceuticals with a Buy rating and $5 price target. Milestone is developing Cardamyst for the treatment of paroxysmal supraventricular tachycardia, the analyst tells investors in a research note. The firm sees a path to resubmission in 2025, and a 2026 approval. The company's current enterprise value of $75M, ascribes a lower probability of resolving the complete response letter than is warranted, contends H.C. Wainwright.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Maintains
$25 → $10
2025-04-01
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$25 → $10
2025-04-01
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$25
2025-03-28
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$25
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$25
2025-03-17
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$25
2025-03-17
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$25
2025-02-28
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$25
2025-02-28
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Milestone Pharmaceuticals Inc (MIST.O) is -2.60, compared to its 5-year average forward P/E of -2.99. For a more detailed relative valuation and DCF analysis to assess Milestone Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.99
Current PE
-2.60
Overvalued PE
-1.54
Undervalued PE
-4.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.99
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.02
Undervalued EV/EBITDA
-2.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
46.42
Current PS
0.00
Overvalued PS
136.87
Undervalued PS
-44.03
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MIST News & Events

Events Timeline

(ET)
2025-11-12
07:16:47
Milestone Pharmaceuticals announces Q3 earnings per share of 12 cents, below consensus estimate of 17 cents.
select
2025-11-03 (ET)
2025-11-03
08:21:57
Milestone Pharmaceuticals to Showcase New Trial Analysis for PSVT
select
2025-08-12 (ET)
2025-08-12
07:18:39
Milestone Pharmaceuticals reports Q2 EPS (20c), consensus (18c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
17:00 PMNASDAQ.COM
PinnedMilestone Pharma Awaits FDA Decision on CARDAMYST, Stock Under Scrutiny

  • FDA Decision on CARDAMYST: Milestone Pharmaceuticals is awaiting a pivotal FDA decision on its lead drug candidate, CARDAMYST nasal spray, for treating paroxysmal supraventricular tachycardia (PSVT), with a target action date set for December 13, 2025.

  • Clinical Trial Support: The NDA submission for CARDAMYST is backed by results from the Phase 3 NODE clinical program, demonstrating efficacy and safety across over 600 patients, with Etripamil showing higher conversion rates than placebo.

  • Financial Position and Milestone Payment: Milestone reported $82.6 million in cash as of September 30, 2025, bolstered by a recent equity offering, and anticipates a $75 million milestone payment upon FDA approval, aiding in a swift commercial launch.

  • Market Impact and Stock Performance: Approval of CARDAMYST could be transformative for Milestone, marking the first new pharmacological option for PSVT in decades, while the company's stock has fluctuated between $0.62 and $2.77 over the past year, closing at $2.64 recently.

[object Object]
Preview
5.0
12-03Globenewswire
Milestone Pharmaceuticals Grants 30,000 Equity Awards to Attract New Employees
  • Equity Incentive Plan: Milestone Pharmaceuticals granted 30,000 options under its 2021 Inducement Plan to attract two new employees, demonstrating the company's commitment to talent acquisition.
  • Option Details: The options have a grant date of December 1, 2025, with an exercise price of $2.69 per share, equal to the closing price on the grant date, aligning new hires' interests with the company's stock performance.
  • Vesting Arrangement: The options will vest over four years, with 25% vesting on the one-year anniversary and the remainder in 36 equal monthly installments, which helps enhance employee retention and long-term commitment.
  • Compliance: This equity award complies with Nasdaq Listing Rule 5635(c)(4), aimed at attracting individuals who were not previously employed by Milestone, ensuring the company's competitiveness in the talent market.
[object Object]
Preview
5.0
12-03Newsfilter
Milestone Pharmaceuticals Grants 30,000 Options to Attract New Employees
  • Employee Incentive Plan: Milestone Pharmaceuticals granted 30,000 options under its 2021 Inducement Plan to attract two new employees, demonstrating the company's commitment to talent acquisition.
  • Option Details: The options have a grant date of December 1, 2025, with an exercise price of $2.69 per share, equal to the closing price on the grant date, ensuring new hires receive fair market value upon joining.
  • Vesting Schedule: The options will vest over four years, with 25% vesting on the one-year anniversary and the remainder in 36 equal monthly installments, which helps enhance employee retention over the long term.
  • Compliance and Strategic Importance: This grant complies with Nasdaq Listing Rule 5635(c)(4), aimed at attracting individuals who were not previously employed, indicating the company's strategic investment in competitive talent acquisition and compliance in the hiring process.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Milestone Pharmaceuticals Inc (MIST) stock price today?

The current price of MIST is 2.64 USD — it has increased 0.76 % in the last trading day.

arrow icon

What is Milestone Pharmaceuticals Inc (MIST)'s business?

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

arrow icon

What is the price predicton of MIST Stock?

Wall Street analysts forecast MIST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIST is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Milestone Pharmaceuticals Inc (MIST)'s revenue for the last quarter?

Milestone Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Milestone Pharmaceuticals Inc (MIST)'s earnings per share (EPS) for the last quarter?

Milestone Pharmaceuticals Inc. EPS for the last quarter amounts to -0.12 USD, decreased -14.29 % YoY.

arrow icon

What changes have occurred in the market's expectations for Milestone Pharmaceuticals Inc (MIST)'s fundamentals?

The market is revising No Change the revenue expectations for Milestone Pharmaceuticals Inc. (MIST) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 46.67%.
arrow icon

How many employees does Milestone Pharmaceuticals Inc (MIST). have?

Milestone Pharmaceuticals Inc (MIST) has 33 emplpoyees as of December 05 2025.

arrow icon

What is Milestone Pharmaceuticals Inc (MIST) market cap?

Today MIST has the market capitalization of 223.14M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free